PRVCF could be ready to bounce back to its 52-week high of 10 cents!

Greetings Traders, Quickly load up PRVCF onto your trading screen and add it to your watch list! The key to good health is not primarily to treat existing symptoms, but to prevent them. This is just one reason why PRVCF looks like a very exciting company to keep your eyes on. PRVCF is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The stock was trading as high as 10 cents this past summer! There could be tremendous bounce potential here, especially if Wall Street continues to learn about how PRVCF could possibly prevent COVID-19. The COVID-19 pandemic has been the biggest challenge for modern society since the Spanish Flu in the early 1900's. Over a million people have lost their lives to the virus and this number is still growing. While big pharmaceutical companies are close to getting a vaccine to market, PRVCF could be ready to shine for its novel Sol-Gel cannibinoid formulation that may actually prevent the virus. PRVCF recently announced successful laboratory development of this cannabinoid Sol-Gel formulation that is a potential prevention/treatment for COVID-19 caused by SARS-CoV-2 infection! Independent scientific literature has reported that high CBD strains could potentially have beneficial properties for the prevention/treatment of SARS-CoV-2 infection. Peer-reviewed hypothesis paper titled "The potential of cannabidiol in the COVID-19 pandemic", dated May 29, 2020, published in the British Journal of Pharmacology: [( Article titled "Cannabidiol Modulates Cytokine Storm in Acute Respiratory Distress Syndrome Induced by Simulated Viral Infection Using Synthetic RNA" published online in September 2020: [( The company has successfully infused a high CBD strain into a proprietary Sol-Gel formulation, which is intended for self-administration using a Sol-Gel nasal spray device. This formulation is now ready for preclinical evaluation for pharmaceutical and nutraceutical applications. It should be noted that PRVCF is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 at this time. CEO Mr. Stephen Van Deventer, commented, "We are very pleased that a high CBD strain-specific Sol-Gel has been successfully formulated with the potential to address COVID-19. The non-invasive, Sol-Gel delivery system, licensed from UniQuest Pty Ltd, is uniquely designed to deliver micelle loaded cannabinoids through trans-mucosal routes, rather than conventional oral routes. This delivery method will avoid hepatic metabolism and allow targeted delivery at the site of action. We will now move towards the start of preclinical assessment with the intention to rapidly move into the clinical trials process." The company has also filed for a provisional patent application for its COVID-19 formulation. PRVCF has filed a provisional application at the Australian Patent Office on November 20, 2020, entitled "Sol-Gel Cannabinoid Formulation and Antiviral Use", application number 20200904291, with the aim of seeking protection for certain cannabinoid formulations and their use in prevention and treatment of COVID-19 caused by SARS-CoV-2 infection. "This patent is a very important patent addition to our library of intellectual properties ("IP"). The provisional application filing for this application will protect our cannabinoid sol-gel IP as we prepare for clinical trials and commercialization of this formulation," remarked Mr. Van Deventer. This may be one of the most opportunistic times to be paying attention to PRVCF as there could be many exciting developments ahead as the company works towards commercialization! The company also has some other exciting things going on in the multi-trillion dollar healthcare arena. PRVCF is additionally staking out important positions in diverse areas such as diabetes and obesity, pain management, neurological disorders and cancer. These are substantial markets that could offer massive revenue opportunities for the company to capitalize on! Current research and development programs include: - Dual gene curative and preventive therapies for diabetes and obesity; - The Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders. - Nature Identical™ peptides for the treatment of various ailments; - Non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; - A therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury) Diabetes and obesity represent a massive market. In the world obesity is a bigger health crisis than hunger, and is the leading cause of death and disabilities around the world with burdens expected to increase in coming years. An alarming [85.2% of people with Type 2 Diabetes]( are overweight or obese! In over five years of multi-disciplinary research, PRVCF's chief research officer Dr. Harry Parekh's team has collectively generated convincing results in models of diabetes, using Smart siRNA and a Tissue Targeted Bio-responsive Carrier System. This program paves the way for preclinical evaluation of proprietary chemistry toward the single gene target implicated in type 2 diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it. The company's gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels. This would in turn help our cells to absorb glucose, thus reducing blood sugar levels and prevent the body from storing excessive fat from our diet. Gene-silencing does not represent a mere management for diabetes and obesity, it represents the potential for a bona fide cure! In cases where patients have a pre-disposition to diabetes or are in the pre-diabetes state, it can be applied as a ‘PreveCeutical’ to halt progress to the full-blown disease. With several programs focused on the trillion dollar healthcare arena and Sol-Gel believed by the company to be the first FDA approved, CBD-based nose-to-brain delivery system, PRVCF could soon be capturing everyone's attention on Wall Street! You can read more about the company's Sel-Gol delivery system and its other programs here: [( With the COVID-19 pandemic still persisting, the company's Sel-Gol formulation has the potential to become a vital preventive treatment! Moderna soared from under $20 to over $170 as the biotech company worked on its coronavirus vaccine. PRVCF is trading at mere pennies right now and could have substantial upside ahead. Especially with a 52-week high of 10 cents hit this past summer. The company is now preparing for clinical trials and commercialization of the Sol-Gel formulation so keep an eye on their news for any developments! The legal marijuana arena has been on fire since the November election and with federal prohibition on its last legs, the explosive rally for pot related stocks could continue. PRVCF may be the next stock on Wall Street to see big moves! Make sure you are ready to get all my alerts FAST by texting the word "Stocks" to "21000" (regular text messaging rates may apply) Also PLEASE take the time to read the following: ( I DO NOT MAKE ANY RECOMMENDATIONS TO BUY OR SELL ANY STOCKS, I JUST PROFILE COMPANIES AND YOU DECIDE WHAT TO DO) Placing a Trade First and foremost, you should always have streaming Level II quotes when trading. I honestly do not know how anyone trades without it! When trading, please follow the below guidelines: Always use a Limit Order: Most brokers won’t even allow you to use Market Orders. Limit Orders allow you to set the price that you want to buy and sell the stock at. This is common knowledge however, you may see some novice traders make the mistake of placing a market order to sell and take out all buyers at the bid, effectively overselling the stock to lower prices. Buy and Sell at the Ask: Many don’t realize that when you buy at the Ask price, you are HELPING the stock price to move up! Once that offer is gone from the shares you purchased, Market Makers could move up to the next offer price as they will see there are buyers at the current price. If you decide to place an order at the bid, you are basically hoping someone will sell their shares to you at this price and you may never get filled and miss the action. It is not always a bad idea to bid sit, as you are creating “bid support”, if you believe the price may come down again and you are not willing to buy higher. Using Stop Limit Orders: Some brokers do not allow you to use stops, however, if you can – it is always a good idea to set your stop loss at the lowest price you are willing to take a loss. You may kick yourself when the stock moves back up and your stop already executed, but remember, there will always be other opportunities and its always best to cut your losses just in case. All or None Orders (Fill or Kill): An example of an all or none order is when someone places an order to buy 100,000 shares @ .01 as an “all or none limit” order. By doing this they are telling the market that they wish to be filled on their entire position at .01 or not to be filled at all. For some reason we have seen market makers ignore these sort of orders on many occasions especially when a stock is on the move. We suggest against it but you will ultimately make the decision. Do Not Chase (ONE OF THE MOST IMPORTANT): Many people want to buy a stock so badly that they end up chasing the stock as it goes up. When they finally fill their order, they may have purchased it too high as traders who bought shares earlier begin to take profit, effectively lowering the stock price and making you a bag holder. Remember, 90% of the time, a stock will always retrace/dip back to an attractive level for you to grab shares. Stock Gaps: If a stock gaps up too high in pre-market, do Not Chase It. A big gap is typically 20-50% or more pre- market or within the first 5-10 minutes of the market opening. Most stocks that gap up will come down again during the day depending on what created the catalyst. Buying is always the catalyst but every once in a while there is earthshattering news on some of these small caps that makes pullbacks unlikely in the short term. Most of the time, when a stock gaps up the market makers will attempt to push it lower starting at this time to try to get investors to panic and sell shares back to them so they can make a profit on any shares they are short from filling orders on the gap. If you like the stock and it gaps up you can usually pick up cheaper shares when and if the market settles back. Sell Into Strength Not Weakness: Once you have taken a position in a stock you need to decide the price you would like to sell your shares. Most would recommend that you put a GTC sell order at that price. Unfortunately as traders have learned to utilize level 2, its best not to do submit GTC sell orders due to the possibility that your order will be represented by a market maker and it will seem as if there is resistance at that level which may compel sellers to get out of their position at a price lower than your price. We suggest that you watch the stock closely and once it hits your price target you can submit your order to sell. It’s important to understand that it’s always best to liquidate the stock into strength and preferably in smaller increments if you have a big position. There you have it!! These are ALL my biased, amateur and unlicensed opinions, should YOU choose freely, knowingly and intelligently to Play ANY of my featured play's!! (Please READ my statement below as well, it will help you understand how I benefit from this newsletter) Also always remember that every single alert I send is very volatile and risky. Any one of them could turn into a big loser. In my personal opinion, no matter how much potential any company has, 99% of the time all that matters is HOW THE STOCK TRADES. If a stock doesn’t trade well, nothing else matters. Don’t believe the hype. Be sure to use a tight stop, book profits quickly on these volatile trades, never let any one trade move too far against you, watch out for gaps, make sure the stock is trading in a healthy way before you enter, and monitor it closely to make sure momentum is positive. It’s always safest to book profits quickly, even on alerts with long-term potential. (Amateur biased unlicensed opinions) I would like to also explain how my Newsletter Makes MONEY!! I DON’T FRONTLOAD, BUY, RECEIVE any SHARES of a Company I Profile!! I NEVER OWN ANY POSITION IN A COMPANY I ALERT/PROFILE!! It would be UNFAIR, WRONG and ILLEGAL for me to have a position in ANY Company I ever Profile on my Newsletter! I am what is known as a STOCK PROMOTER!! I just wanted to address this issue for some people who might think I trade the companies I profile on my Newsletter or I own a position before or during the time I profile them!!! The honest truth is I DO NOT!!….. I do get CASH compensation to profile companies most of the times I talk about them in my Newsletter, this is HOW I MAKE MONEY and pretty much how 99% of ALL the other Newsletters out there make money…… Most of you have signed up to my Newsletter because of an advertisement you saw, well it costs money to run those advertisements…. I ALWAYS Disclose how much and who paid me in my Disclaimer at the end of each e-mail!!! Here is some information directly from the SEC Website: Tips for Checking Out Newsletters “Find out whether the newsletter received payment to “tout” or recommend the stock and, if so, what it received and from whom. Because the U.S. Constitution’s First Amendment protects freedom of speech, the SEC cannot simply prohibit newsletters from recommending or touting particular stocks. But when newsletters receive payment for touting, the securities laws require them to disclose specifically who paid them, the amount, and the type of payment (cash, stock, or some other thing of value). Read carefully what the newsletter says about payments it receives. Be suspicious of newsletters that do not specifically disclose these items: who paid them, the amount, and the type of payment. The following examples raise red flags because they do not contain specific information: “From time to time, XYZ Newsletter may receive compensation from companies we write about.” “From time to time, XYZ Newsletter or its officers, directors, or staff may hold stock in some of the companies we write about.” “XYZ Newsletter receives fees from the companies we write about in our newsletter.” Think twice about newsletters that bury their disclosures or put them in tiny, hard-to-read typeface. Legitimate online newsletters that have been paid to tout stocks will clearly and specifically tell investors who paid them, the amount, and the type of payment. Look for their disclosure statements in articles about particular companies or in a list or chart on their websites.” I hope this answers a lot of your questions and also gives you a better perspective to my play’s the Next Time you see one!! Don’t forget to tell everyone you know about PTE.la and help my Newsletter Grow!! Remember to trade smart, research your options, and use due diligence! Sincerely, PTE.la © 2020 PTE.la PTE, LLC (publisher of PTE.la) is NOT registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for PTE, LLC may have long or short positions in securities that may be discussed on this website or newsletter. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are simulated figures from virtual simulated portfolios. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. PTE.la’s sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by PTE.la or an offer or solicitation to buy or sell any security. Neither the owner of PTE.la nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with alicensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit . PTE.la makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors. PTE.la is owned and operated by PTE LLC. PTE LLC has been compensated up to Twenty-Five Thousand Dollars Cash by a third party Electrik Dojo to conduct investor relations advertising and marketing for PRVCF. Any compensation received by PTE LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. A third party of PTE LLC may have shares and may liquidate, which may negatively affect the stock price. PTE LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. Some of the content in this release contains forward - looking information within the meaning of Section 27 A of the Securities Act of 1 9 9 3 and Section 21 E of the Securities Exchange Act of 1 9 3 4 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward - looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, acompany’s past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable. PTE.la makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. PTE Team 9 Downing street Newark NJ 07105 USA [Unsubscribe]( [Change subscriber options](